High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma with or without antiretroviral therapy during antineoplastic agents

Ann Oncol. 2003 Dec;14(12):1792-4. doi: 10.1093/annonc/mdg484.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Antiviral Agents / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Disease-Free Survival
  • Female
  • Humans
  • Idarubicin / administration & dosage
  • Lymphocyte Count
  • Lymphoma, AIDS-Related / drug therapy*
  • Lymphoma, AIDS-Related / pathology
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / pathology
  • Male
  • Middle Aged
  • Vincristine / administration & dosage

Substances

  • Antiviral Agents
  • Vincristine
  • Dexamethasone
  • Cyclophosphamide
  • Idarubicin

Supplementary concepts

  • CIOD protocol